Journal
CELL CHEMICAL BIOLOGY
Volume 27, Issue 2, Pages 197-+Publisher
CELL PRESS
DOI: 10.1016/j.chembiol.2019.10.012
Keywords
-
Categories
Funding
- NCI NIH HHS [R01 CA187678, P30 CA016042, T32 CA009120] Funding Source: Medline
- BLRD VA [I01 BX001919] Funding Source: Medline
Ask authors/readers for more resources
Biosynthesis of the pyrimidine nucleotide uridine monophosphate (UMP) is essential for cell proliferation and is achieved by the activity of convergent de novo and salvage metabolic pathways. Here we report the development and application of a cell-based metabolic modifier screening platform that leverages the redundancy in pyrimidine metabolism for the discovery of selective UMP biosynthesis modulators. In evaluating a library of protein kinase inhibitors, we identified multiple compounds that possess nucleotide metabolism modifying activity. The JNK inhibitor JNK-IN-8 was found to potently inhibit nucleoside transport and engage ENT1. The PDK1 inhibitor OSU-03012 (also known as AR-12) and the RAF inhibitor TAK-632 were shown to inhibit the therapeutically relevant de novo pathway enzyme DHODH and their affinities were unambiguously confirmed through in vitro assays and co-crystallization with human DHODH.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available